MAVENIR
20.2.2024 09:01:26 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announces a significant expansion of its OpenBeam™ radio portfolio with the launch of three new next-generation platforms that deliver advanced capabilities across diverse scenarios. This major enhancement of the OpenBeam solution set will further accelerate the deployment of 3GPP and O-RAN-compliant radios, with a focus on energy efficiency and engineered to support ULPI (Uplink Performance Improvement) functionality for Active Antenna Units (AAUs), in addition to the current O-RAN 7.2b specification.
Mavenir’s extended OpenBeam radio platform delivers an unparalleled breadth and depth of solutions that are AI-enabled and ‘green by design’, comprising:
- Wideband mMIMO AAUs: Mavenir’s next generation 64TRX massive MIMO AAU with up to 600MHz instantaneous bandwidth for Communication Service Providers (CSPs) with access to broad spectrum ranges. This halves the number of AAUs needed for deployment thereby streamlining network operations and reduces total cost of ownership.
- Wideband Multi-Band RRUs: Mavenir’s complete set of Remote Radio Units (RRUs) that support multiple bands with wideband power amplifiers – offering up to 480W output power and mid-band tri-band solution, in addition to the low-band tri-band solution already available as part of the OpenBeam portfolio. Wideband radio architecture allows operators to share power dynamically between bands, providing an overall improvement in energy efficiency.
- Next-Generation 32TRX mMIMO AAUs: Mavenir’s new generation of 32TRX Active Antenna Units (AAUs) powered by the Qualcomm® QRU100 5G RAN Platform to enhance performance, energy efficiency, and features for massive MIMO deployments.
In addition to the current O-RAN 7.2b specification, Mavenir’s AAU solutions are also engineered to support ULPI (Uplink Performance Improvement) allowing network operators to improve uplink performance, minimize latency, and reduce fronthaul bandwidth, especially in urban settings where network demand is high.
Mavenir's innovation and leadership in OpenBeam radio solutions have been recognized by global intelligence company ABI Research, which ranked Mavenir as the overall leader and top innovator in its recent Open RAN vendor comparison report (November 2023). The report praised Mavenir for addressing diverse industry needs with its broad portfolio of radio products spanning Micro, Macro, Millimetre Wave and mMIMO.
Job Benson, SVP, GM, Radio Business Unit at Mavenir said: “In live deployments across the world, our OpenBeam portfolio is demonstrating its value as a compelling enabler of growth for operators, providing radio solutions with the agility, cost-efficiency, and intelligence to meet critical network demands today, and a robust innovation platform as networks evolve and expand. Mavenir is pursuing an active programme of development to continuously enhance the features and capabilities of our standard-setting OpenBeam platforms, providing Communication Service Providers with the best-in-class solutions for their radio access network needs.”
Mavenir’s OpenBeam™ full radio portfolio will be displayed at the upcoming Mobile World Congress in Barcelona, Feb 26-29, in Hall 2 Stand 2H60. For more on Mavenir’s presence at the show visit www.mavenir.com/mwc-2024
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 300+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
For more information, please visit www.mavenir.com
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220628570/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom